3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (August 2023)
35 slides from 3b Blackbio Dx's investor presentation, Aug 11, 2023
Slide 1: Cover letter to BSE
Ref. No.P-66/ August 11, 2023 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agrochemicals and Diagnostic Kits (Health Care) for yo
Slide 2: Investor Presentation August 2023
Farmer’s Trusted Agro-Input Partner for 51 Years Reliable and Affordable Healthcare Diagnostic Solutions Experts in Molecular Diagnostics throughout Europe INVESTOR PRESENTATION August, 2023
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation t
Slide 4: Financial Performance and Key Highlights
FINANCIAL PERFORMANCE AND KEY HIGHLIGHTS Since 1972, 51 Years Strong ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 5: Performance Highlights – Q1 FY 2023-24
Performance Highlights – Q1 FY 2023-24 1724.24 919.08 KILPEST (Consolidated) Q1 FY23 Q1 FY24 1292.29 621.63 Total Revenue 1292.29 1724.32 Profit Before tax 621.63 919.08 Profit After tax 471.32 720.55 Q1 2022-23 Q1 2023-24 Q1 2022-23 Q1 2023-24 Paid-Up Equity Share Capital 750.81 750.81 Total Sales
Slide 6: We Are Proud To Be A Part Of
WE ARE PROUD TO BE A PART OF minha BEST: 3 2021
Slide 7: Key Highlights - Agrochemicals
Key Highlights - Agrochemicals Main Thrust Area of R&D Development of novel formulations for agriculture and public health which are less harmful and cost effective. Performance monitoring of existing products/process. Improvement in existing products/process with a customer driven approach. F
Slide 8: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 • Health &
Slide 9: From the house of Kilpest India Ltd.
Since 1972 From the house of Kilpest India Limited, KILPEST INDIA LTD. India’s most trusted agro-chemical brand proudly brings First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GEN
Slide 10: Introduction – 3B BlackBio Biotech India Limited
Introduction – 3B BlackBio Biotech India Limited Incorporated in the year 2011, “3B BlackBio Biotech India Limited”, a subsidiary of Kilpest India Limited, is engaged in Design, Development, Manufacturing and Commercialization of Rapid tests, qPCR tests & NGS based Molecular Diagnostic Kits for re
Slide 11: TRUPCR from 3B BlackBio Biotech: Vision and Mission
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Our Vision: Our Mission: To offer reliable, affordable and To design and develop molecular effective healthcare solutions to all by diagnostics products of superior quality recognizing the great potential of and value that continuously improves biotechnology
Slide 12: TRUPCR Growth Story
TRUPCR® Growth Story 2023: Headcount: 40 Revenue: ₹ 505.16 Million ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH Products: 120+ PUBLIC HEALTH HUMAN GENETICS
Slide 13: Growth Canvas: Sales in INR Millions
Growth Canvas Sales in INR Millions ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 14: Financial Highlights – Q1 FY 23-24
Financial Highlights – Q1 FY 23-24 898.43 1,202.89 942.51 600.41 Revenue from Operations EBITDA Q1 FY 2022-23 Q1 FY 2023-24 886.85 696.51 590.04 447.69 PBT PAT Rs. In Lakhs. ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 15: Portfolio Expansion, Market Penetration, Geographical Reach
Portfolio Expansion: Market Penetration: With our extensive R&D We plan to increase our sales with experience, we plan to increase existing customers / channel our product portfolio by launching partners by adding more products new products in Rapid Antigen to their current portfolio. Vertical, qPCR
Slide 16: Business Outlook
Business Outlook Our Q1 Sales have been INR 1202.89 Lakhs (This includes COVID Sales of INR 36.63 Lakhs). Sales from TRUPCR Europe Limited, Manchester for INR 168.29 Lakhs have also been consolidated in the Q1 sales figures. In Q1 2023-24, the Export Sale for molecular diagnostic kits was INR 163.50
Slide 17: Exports / International Business
Exports / International Business TRUPCR® assays have been well-accepted in over 35 countries across UK and Europe, Middle East, APAC, LATAM and United States of America. We have added few more countries across South-East Asia and Middle-East through our channel partners. We are working to add more c
Slide 18: Events & Conferences
Events & Conferences We have been exhibiting a strong national and international presence by participating in multiple conferences to promote our product range and launch new product verticals. During 16th August 2023-18th August 2023, we will be exhibiting in Medlab Asia 2023 which is being held at
Slide 19: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site • In line with our vision for growth and enabling further support to our growing customer base, TRUPCR® Europe Limited has moved to a new and larger, self-contained, state of the art facility with dedicated labs for Production, QC and R&D, along with a separa
Slide 20: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site TRUPCR Europe has been participating in International Molecular Diagnostic Conferences and arranging trainings & seminars for the customers. With these conferences, the visibility of TRUPCR Europe is increasing and we are getting enquiries for providing distr
Slide 21: TRURAPID Rapid Kit Business Vertical
Rapid Kit Business Vertical Our Rapid Kit manufacturing plant is ready & we are optimizing the products in R&D which have market potential, other than COVID Testing Kits. TRURAPID® The Need: As per WHO, AMR remains one of the top 10 global public health threats facing humanity, associated with the d
Slide 22: Rapid Diagnostic Tests for Carbapenemase Detection
Rapid Kit Business Vertical Launching In-vitro Rapid Diagnostic Tests for the Detection of Carbapenemes and ß-lactamases Resistance in Bacterial Culture / Blood Culture* TRURAPID® TRURAPID® In vitro rapid diagnostic test for the detection of In vitro rapid diagnostic test for the detection of OXA-48
Slide 23: Next-Gen Sequencing (NGS) Vertical
Next-Gen Sequencing (NGS) Vertical We started working on NGS Kit development in 2019, had developed few parameters, but then COVID came and all activities were suspended. Now we are again reviving the NGS kits revalidations and also development of few more parameters, keeping in mind the global mark
Slide 24: Scheme of Amalgamation, Utilization of Funds, Proposed NSE Listing
Scheme of Amalgamation The Hon'ble National Company Law Tribunal, Indore Bench vide its order dated 04th August 2023 has approved the Scheme of Amalgamation between 3B BlackBio Biotech India Ltd (Transferor Company) and Kilpest India Ltd (Transferee Company). The company has started taking up the ne
Slide 25: R&D and People
R&D R&D People •Highly educated team of scientist from varied backgrounds •Dedicated teams for respective segments •Separate onco team headed by researchers (Ph.Ds.) from oncology background •Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background L
Slide 26: Product QC - Our Strength
Product QC - Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 27: Quality & Regulatory
Quality & Regulatory ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India Over 120 Parameters are CE-IVD marked ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUM
Slide 28: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Mass Spec Hybridization Sanger Sequencing Next Generation Sequencing Low Volume Microarray ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 29: Product Segments
Product Segments ONCOLOGY ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 30: All Inclusive TRUPCR Products
All Inclusive TRUPCR® Products TRUPCR® range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis Sample stabilization TRUPCR ® Nu
Slide 31: Global Recognition
Global Recognition ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 32: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs • Evolution of disease profiles. New viruses and cancers are been diagnosed External Growth Drivers • Increase in evidence-based treatments /
Slide 33: Outstanding Achievement Award for Excellence in R&D, FMPCCI 2022
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal - 2022 3B BlackBio Biotech India Limited received the Outstanding Achievement Award – 2021 by the Honorable Governor of Madhya Pradesh, His Excellency Shri Mangubhai Patel. The award was conferred to us in recognition of our conti
Slide 34: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 35: Jai Hind
JAI HIND ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS